Viruses, Vol. 16, Pages 661: T-Cell Responses to COVID-19 Vaccines and Breakthrough Infection in People Living with HIV Receiving Antiretroviral Therapy
Viruses, Vol. 16, Pages 661: T-Cell Responses to COVID-19 Vaccines and Breakthrough Infection in People Living with HIV Receiving Antiretroviral Therapy
Viruses doi: 10.3390/v16050661
Authors:
Sneha Datwani
Rebecca Kalikawe
Rachel Waterworth
Francis M. Mwimanzi
Richard Liang
Yurou Sang
Hope R. Lapointe
Peter K. Cheung
Fredrick Harrison Omondi
Maggie C. Duncan
Evan Barad
Sarah Speckmaier
Nadia Moran-Garcia
Mari L. DeMarco
Malcolm Hedgcock
Cecilia T. Costiniuk
Mark Hull
Marianne Harris
Marc G. Romney
Julio S. G. Montaner
Zabrina L. Brumme
Mark A. Brockman
People living with HIV (PLWH) can exhibit impaired immune responses to vaccines. Accumulating evidence indicates that PLWH, particularly those receiving antiretroviral therapy, mount strong antibody responses to COVID-19 vaccines, but fewer studies have examined cellular immune responses to the vaccinations. Here, we used an activation-induced marker (AIM) assay to quantify SARS-CoV-2 spike-specific CD4+ and CD8+ T cells generated by two and three doses of COVID-19 vaccines in 50 PLWH receiving antiretroviral therapy, compared to 87 control participants without HIV. In a subset of PLWH, T-cell responses were also assessed after post-vaccine breakthrough infections and/or receipt of a fourth vaccine dose. All participants remained SARS-CoV-2 infection-naive until at least one month after their third vaccine dose. SARS-CoV-2 infection was determined by seroconversion to a Nucleoc...
Source: Viruses - Category: Virology Authors: Sneha Datwani Rebecca Kalikawe Rachel Waterworth Francis M. Mwimanzi Richard Liang Yurou Sang Hope R. Lapointe Peter K. Cheung Fredrick Harrison Omondi Maggie C. Duncan Evan Barad Sarah Speckmaier Nadia Moran-Garcia Mari L. DeMarco Malcolm Hedgcock Cecili Tags: Article Source Type: research